Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06696690

The Safety and Efficacy of Median Nerve Electrical Stimulation for Improving Neurological Function Prognosis in Patients With Cardiac Arrest

Median nerve stimulation (MNS), a non-invasive brain stimulation technique, has been widely adopted in clinical arousal therapies and multiple clinical investigations have attested to the efficacy of this technique; nevertheless, evidence concerning the application of MNS in improving the neurological prognosis of patients with return of spontaneous circulation (ROSC) following cardiac arrest (CA) remains scarce. The current study endeavors to assess the safety and efficacy of MNS treatment in enhancing the neurological prognosis of CA patients after ROSC and it is designed as a multicenter, prospective, randomized controlled trial with an estimated sample size of 400 patients. Eligible patients will be randomly allocated in a 1:1 ratio to either receive MNS treatment or sham stimulation treatment for 8 hours per day for 14 consecutive days and the primary outcome measure is the proportion of patients in each group with a Cerebral Performance Category (CPC) score ranging from 1 to 2, 6 months after randomization, which will help to determine the effectiveness of MNS in providing neuroprotection for patients with ROSC after CA.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Median Nerve Coma Consciousness Disorders Nervous System Diseases Neurobehavioral Manifestations Neurologic Manifestations Pathological Conditions, Signs and Symptoms Post Cardiac Arrest Brain Injury Signs and Symptoms Unconsciousness

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years old.
  • Hemodynamics remains continuously stable for ≥ 7 days.
  • There is still a lack of purposeful movements after the return of spontaneous circulation following cardiopulmonary resuscitation.
  • Advanced life support is provided within 6 hours after the return of spontaneous circulation (ROSC).

Exclusion criteria

  • Patients with hemodynamic instability.
  • Pregnant patients.
  • Those who have abnormal anatomical structures on the median nerve conduction pathway and are unable to receive electrical stimulation.
  • Patients with a confirmed history of epilepsy before admission or during hospitalization.
  • Patients with severe arrhythmia or those who have pacemakers implanted.
  • Patients whose family members do not agree to their enrollment in the study.

Treatment and study plan

MNS

Device

The MNS treatment group use the NeuroTrac™ Multi-TENS transcutaneous electrical stimulator to provide an asymmetric biphasic pulse train with a frequency of 35 Hz, an amplitude of 20 mA and a pulse width of 300 ms, which is on for 20 seconds and off for 50 seconds. The treatment lasts for 8 hours per day and the treatment course lasts for one week.

Sham stimulation

Device

The sham stimulation treatment group utilized the same stimulation device and was subjected to a safe yet ineffective stimulation protocol for sham stimulation. The treatment lasts for 8 hours per day and the treatment course lasts for 14 days.

Primary outcomes

  1. The proportion of patients with a CPC score of 1-2

    Time frame: 180 days

    The primary outcome is the proportion of patients with a score of 1-2 at 180 days after randomization in each group. Favorable: 1 means full recovery or mild disability; 2 means moderate disability but independent in activities of daily living (ADLs). Unfavorable: 3 means severe disability-Dependent in ADLs; 4 means persistent vegetive state; 5 means Death.

Study contacts

Contact information is provided by the study sponsor or research team.

Ziren Tang, Prof.

CONTACT

[email protected]

+86 010-85231530

Sponsors and collaborators

Lead sponsor

Tang Ziren

Other

Registry information

Official study title

The Safety and Efficacy of Median Nerve Electrical Stimulation for Improving Neurological Function Prognosis in Patients With Cardiac Arrest: A Multicenter, Prospective, Randomized Controlled Study

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Nov 20, 2024
Registry last updated
Apr 11, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.